AzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819
DELRAY BEACH, Fla., Jan. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company...
Study Examines Effects of Socioeconomics on Health of Youngsters
Children with cystic fibrosis (CF) who live in more socioeconomically disadvantaged areas of the U.S. tend to have worse lung function...
Cholesterol Metabolism Impaired in CF Mouse Model
The metabolism of cholesterol is impaired in a mouse model of cystic fibrosis, a preliminary study suggests. In the model, there seems to...
Inhaled-IV Antibiotic Combo May Better Treat Acute Flares Than IV-only Mix
When given alongside the antibiotic Colistin (colistimethate), Cayston (aztreonam lysine), an inhaled antibiotic specifically targeting...
Study Examines Effects of Socioeconomics on Health of Youngsters
Children with cystic fibrosis (CF) who live in more socioeconomically disadvantaged areas of the U.S. tend to have worse lung function...
New strategy to accelerate diagnosis and improve treatment of rare diseases
Rare Disease Framework sets out vision to improve the lives of more than 3.5 million people with rare diseases in the UK The framework...
Small Study Shows Tobramycin Safely Treats Lung Infection in Infants With CF
Inhaled antibiotic tobramycin safely eradicated early Pseudomonas aeruginosa infection in cystic fibrosis (CF) patients younger than a...
Arcturus to Develop ARCT-032 as RNA Therapy for CF
Arcturus Therapeutics has selected ARCT-032, an aerosolized RNA-based therapy, to be developed as a novel therapeutic candidate for...
FDA Expands Use of Three Cystic Fibrosis Medications
The Food and Drug Administration (FDA) has expanded the approval of Trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor; Vertex),...
